De Novo Pharmatech
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An AI-powered drug discovery company designing novel small molecules for challenging targets.
Oncology
Technology Platform
An AI-powered platform for de novo small molecule design and optimization, integrating deep learning and computational chemistry to tackle difficult drug targets.
Opportunities
Potential to unlock novel biology and generate valuable intellectual property by drugging intractable targets through computational design.
Risk Factors
Platform risk: the ultimate validation requires delivering clinical-stage assets, and the field is crowded with well-funded competitors.
Competitive Landscape
Operates in a highly competitive global AI drug discovery sector, requiring clear differentiation in hit-finding efficiency or compound quality.